Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Womens Health which include indications Cytomegalovirus (HHV-5) Infections, Chlamydia Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
- The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

TABLE OF CONTENTS

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
AlphaVax Inc
Citranvi Biosciences LLC
Helocyte Biosciences Inc
Merck & Co Inc
Stadius Biopharma LLC
Trellis Bioscience Inc
VBI Vaccines Inc
Yaso Therapeutics Inc
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
AVX-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM
May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM
Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients
Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
Sep 11, 2019: VBI to study cancer vaccine with GSKs adjuvant system
Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AlphaVax Inc, 2021
Pipeline by Citranvi Biosciences LLC, 2021
Pipeline by Helocyte Biosciences Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Stadius Biopharma LLC, 2021
Pipeline by Trellis Bioscience Inc, 2021
Pipeline by VBI Vaccines Inc, 2021
Pipeline by Yaso Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

RELATED REPORTS

Human SARS Coronavirus 2 Spike Glycoprotein (E2 or Peplomer Protein or S) - Drugs in Development, 2021

Human SARS Coronavirus 2 Spike Glycoprotein (E2 or Peplomer Protein or S) - Drugs in Development, 2021Human SARS Coronavirus 2 Spike Glycoprotein (E2 or Peplomer Protein or S) - Drugs

USD 3500 View Report

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 2.3.2.26) - Drugs in Development, 2021

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A

USD 3000 View Report

Human Cytomegalovirus Glycoprotein H (gH) - Drugs in Development, 2021

Human Cytomegalovirus Glycoprotein H (gH) - Drugs in Development, 2021Human Cytomegalovirus Glycoprotein H (gH) - Drugs in Development, 2021 provides in depth analysis on Human Cytomegalovirus Glycoprotein H (gH) targeted

USD 3000 View Report

Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2020

Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2020Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein

USD 3500 View Report

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

Human SARS Coronavirus 2 Spike Glycoprotein (E2 or Peplomer Protein or S) - Drugs in Development, 2021

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 2.3.2.26) - Drugs in Development, 2021

Human Cytomegalovirus Glycoprotein H (gH) - Drugs in Development, 2021

Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2020

FAQs